Zealand Pharma finishes phase III enrollment

All patients have been found for a phase III study of a potential hyperinsulinism treatment for children, reports Zealand Pharma.

Photo: Zealand Pharma / PR

Zealand Pharma has announced that recruitment for an upcoming phase III study with a drug candidate, dasiglucagon, designed to treat infants up to 12 months of age with congenital hyperinsulinism (CHI), has been completed, a company press release reports.

The rare pediatric condition leads to increased insulin levels due to a genetic defect in insulin producing cells, resulting in recurrent low blood sugar levels throughout childhood. Existing treatments are ”limited, complex and may be insufficient,” the statement reads.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs